Track Evaxion Biotech A/S — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

Evaxion Biotech A/S EVAX Open Evaxion Biotech A/S in new tab

4.09 USD
EPS
-1.00
P/B
1.92
ROE
-100.18
Beta
0.27
Target Price
11.25 USD
Evaxion Biotech A/S logo

Evaxion Biotech A/S

🧾 Earnings Recap – Q3 2025

Evaxion reported a strong Q3 2025, highlighted by a transformative deal with MSD, marking a significant milestone in their AI-driven vaccine development and extending their cash runway into 2027.

  • MSD exercised their option on the AI-discovered vaccine candidate EVX-B3, generating a $7.5 million exercise fee that enhances financial stability.
  • Two-year clinical efficacy data for EVX-01 showed a promising 75% objective overall response, generating sustained T cell activity across patients.
  • Introduction of EVX-04, targeting acute myeloid leukemia, expands Evaxion’s pipeline, underscoring their commitment to precision cancer vaccines.
  • Investment in an upgraded AI-Immunology platform with an automated vaccine design module optimizes development processes and cost efficiency.
  • Cash runway extended to the second half of 2027, ensuring ongoing R&D and business development initiatives.
📅
1M 6M YTD 1Y 2Y 5Y Max
Loading chart...
Key Metrics
Earnings dateAug. 13, 2026
EPS-1.00
Book Value2.04
Price to Book1.92
Debt/Equity44.04
% Insiders17.469%
Growth
Revenue Growth-1.00%
Estimates
Forward P/E35.64
Forward EPS0.11
Target Mean Price11.25

DCF Valuation

Tweak assumptions to recompute fair value for Evaxion Biotech A/S (EVAX)
Currency: USD
DCF Assumptions
Decimal (e.g., 0.10 = 10%). Range allows declines (−50%) to strong growth (+50%).
Decimal (e.g., 0.30 = 30%).
Decimal (e.g., 0.04 = 4%).
Decimal (e.g., 0.20 = 20%).
Percent number (e.g., 3 = 3%).
Percent number (e.g., 10 = 10%).
Percent number (e.g., 5 = 5%).
DCF Result
Fair Value (DCF)
—
Current Price
—
Upside
—
WACC
—
Terminal PV
—
Σ PV of FCFs
—
Note: historical bars show reported FCF (for context); forward bars show PV of projected FCF; if no per-year data, totals are shown.

Evaxion Biotech A/S Logo Evaxion Biotech A/S Analysis (EVAX)

Denmark Health Care Official Website Stock

Is Evaxion Biotech A/S a good investment? Evaxion Biotech A/S (EVAX) is currently trading at 4.09 USD. Market analysts have a consensus price target of 11.25 USD. This suggests a potential upside from current levels.

Earnings Schedule: Evaxion Biotech A/S is expected to release its next earnings report on Aug. 13, 2026. The market consensus estimate for Forward EPS is 0.11.

Investor FAQ

Does Evaxion Biotech A/S pay a dividend?

No, it does not currently pay a dividend.

What asset class is Evaxion Biotech A/S?

Evaxion Biotech A/S is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.

When is the next earnings date?

The next earnings date is projected to be Aug. 13, 2026. The company currently has a trailing EPS of -1.00.

Company Profile

Evaxion A/S, a clinical-stage biotech company, develops artificial intelligence-powered immunology vaccines. The company develops EVX-01, which is in phase 2 global multi-center clinical trial for the treatment of advanced melanoma; EVX-03, DNA-based cancer vaccine for the treatment of solid tumors; and EVX-04, a therapeutic cancer vaccine candidate, which is in phase 1 trial for acute myeloid leukemia. Its programs also include vaccines that are in pre-clinical stage, which includes EVX-B1, a multi-component prophylactic vaccine targeting skin and soft tissue infections with S. aureus bacteria; EVX-B2 to target multi-component prophylactic vaccine against gonorrhea bacteria; EVX-B3 to target bacterial pathogen associated with repeated infections; and EVX-V1, a multi-component prophylactic vaccine candidate for cytomegalovirus. The company was formerly known as Evaxion Biotech A/S and changed its name to Evaxion A/S in May 2025. Evaxion A/S was incorporated in 2008 and is based in Horsholm, Denmark.

Exchange Ticker
NMS (United States) EVAX

Dividends

Historical Split Corporate Actions

Split Date Split Ratio to 1
Jan. 22, 2024 0.100000
Jan. 14, 2025 0.200000
Trades
Trade History
No trades yet
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion